Drug Search Results

Pinatuzumab vedotin

Alternative Names: pinatuzumab vedotin
Latest Update: 2024-04-22
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: CD22 Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Pinatuzumab vedotin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Diffuse Large B-Cell Lymphoma|Lymphoma, Non-Hodgkin|Follicular Lymphoma

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
2011-004377-84	P2	Completed	Lymphoma, Non-Hodgkin\|Follicular Lymphoma\|Diffuse Large B-Cell Lymphoma	2019-02-07
ROMULUS	P2	Completed	Diffuse Large B-Cell Lymphoma\|Follicular Lymphoma\|Lymphoma, Non-Hodgkin	2017-03-08

Recent News Events

Date	Type	Title
04/22/2024	PubMed	Monomethyl Auristatin E (MMAE), a Payload for Multiple Antibody Drug Conjugates (ADCs), Demonstrates Differential Red Blood Cell Partitioning Across Human and Animal Species.
02/01/2021	PubMed	An Anti-CD22-seco-CBI-Dimer Antibody-Drug Conjugate (ADC) for the Treatment of Non-Hodgkin Lymphoma That Provides a Longer Duration of Response than Auristatin-Based ADCs in Preclinical Models.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions